Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab

BACKGROUND: The aberrant expression of HER2 is highly associated with tumour occurrence and metastasis, therefore HER2 is extensively targeted for tumour immunotherapy. For example, trastuzumab and pertuzumab are FDA-approved monoclonal antibodies that target HER2-positive tumour cells. Despite thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Wu, Shanshan, Zhuang, Xinlei, Weng, Gaoqi, Fan, Jiansheng, Yang, Xiaoyue, Xu, Yingchun, Pan, Liqiang, Hou, Tingjun, Zhou, Zhan, Chen, Shuqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941612/
https://www.ncbi.nlm.nih.gov/pubmed/31920346
http://dx.doi.org/10.2147/OTT.S232912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941612/
https://www.ncbi.nlm.nih.gov/pubmed/31920346
http://dx.doi.org/10.2147/OTT.S232912

Ejemplares similares